LARTIA TRIAL
• 217 patients
• 50 adapted
• Median dose 60Gy
• Median follow-up 25.8 months
• 30% local recurrence rate
• 20% infield
• 6% marginal
• 4% out of field
Ramella et al. JTO, 2018